Selecting and using nebuliser equipment

Thorax

Volumn 52, Issue SUPPL. 2, 1997, Pages

  Kendrick, A H ^a   Smith, E C ^a   Wilson, R S E ^b  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b PRINCESS ROYAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DORNASE ALFA; FENOTEROL PLUS IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; MUCOLYTIC AGENT; PENTAMIDINE; SALBUTAMOL; SODIUM CHLORIDE; TERBUTALINE; UNCLASSIFIED DRUG;

COST; CROSS INFECTION; EQUIPMENT; FACE MASK; FLOW RATE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MEDICAL NEBULIZER; NEBULIZATION; PARTICLE SIZE; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW;

EID: 0030988266     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.52.2008.s92     Document Type: Review

References (48)

1. Brain JD, Valberg PA. Deposition of aerosol in the respiratory tract. Am Rev Respir Dis 1979;120:1325-73.
2. O'Callaghan C. How to get drugs into the respiratory tract. Arch Dis Child 1993;68:441-3.
3. Rees BJ, Clark TJH. The importance of particle size in response to inhaled bronchodilators. Eur J Respir Dis 1982; 63(Suppl 119):73-8.
4. Swift DL. Generation and respiratory deposition of therapeutic aerosols. Am Rev Respir Dis 1980;122:71-7.
5. Mercer TT. Production and characterisation of aerosols. Arch Intern Med 1973;131:39-50.
6. Byron PR. Aerosol formulation, generation and delivery using non-metered systems. In: Byron PR, ed. Respiratory drug delivery. Florida: CRC Press, 1990: 143-66.
7. Smith EC, Denver J, Kendrick AH. Comparison of 23 nebuliser/compressor combinations for domiciliary use. Eur Respir J 1995;8:1214-21.
8. Dennis JH, Stenton SC, Beach JR, Avery AJ, Walters EH, Hendrick DJ. Jet and ultrasonic nebuliser output: use of a new method for direct measurement of aerosol output. Thorax 1990;45:728-33.
9. Kendrick AH, Smith EC, Denver J. Nebulisers - fill volume, residual volume and matching of nebuliser to compressor. Respir Med 1995;89:157-9.
10. Clay MM, Pavia D, Newman SP, Clarke SW. Factors influencing the size distribution of aerosols from jet nebulisers. Thorax 1983;38:755-9.
11. Douglas JG, Leslie MJ, Crompton GK, Grant IWB. Is the flow rate used to drive a jet nebuliser clinically important? BMJ 1985;290:29-32.
12. Denver J, Dyche T, Smith EC, Kendrick AK. The optimum volume for nebulization of bronchodilators. Eur Respir J 1993;6(Suppl 17):148s
13. Newman SP, Pellow PGD, Clarke SW. Drop sizes from medical atomisers (nebulisers) for drug solutions of different viscosities and surface tensions. Atom Spray Technol 1987;3:1-11.
14. Steventon RD, Wilson RSE. A guide to apparatus for home nebulization therapy. Allen and Hanburys Ltd, 1986.
15. Hurley PK, Smye SW. Assessment of antibiotic aerosol generation using commercial jet nebulisers. J Aerosol Med 1994;7:217-28.
16. Ho KKL, Kellaway IW, Tredree RL. An evaluation of powered nebulisers. Health Equipment Information No 180. Department of Health and Social Security, 1980.
17. Clay MM, Pavia D, Newman SP, Lennard-Jones T, Clarke SW. Assessment of jet nebulisers for lung aerosol therapy. Lancet 1983;ii:592-4.
18. Everard ML, Clarke AE, Milner AD. Drug delivery from jet nebulisers. Arch Dis Child 1992;67:586-91.
19. Hurley PK, Smye SW. Performance assessment of a range of commercial jet nebulisers. Technol Health Care 1994;1: 209-14.
20. Loffert DT, Ikle D, Nelson HS. A comparison of commercial jet nebulisers. Chest 1994;106:1788-92.
21. Phillips P, Fisher B, Toyick N, Jenkins V. Performance evaluation of nebulisers. Report for the Welsh Office. Surgical Materials Testing Laboratory, Bridgend General Hospital, 1993.
22. Smye SW, Shaw A, Norwood HM, Littlewood JM. Some factors affecting the efficiency of a jet nebuliser system. Clin Phys Physiol Med 1990;11:167-75.
23. Newman DM, Lipworth BJ. Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream"). Thorax 1994;49:762-70.
24. Newman SP, Pellow PGD, Clay MM, Clarke SW. Evaluation of jet nebulisers for use with gentamicin solution. Thorax 1985;40:671-6.
25. Newman SP, Pellow PGD, Clarke SW. Efficient nebulization of powdered antibiotics. Int J Pharm 1987;36:55-60.
26. Newman SP, Pellow PGD, Clarke SW. Choice of nebulisers and compressors for delivery of carbenicillin aerosol. Eur J Respir Dis 1986;69:160-8.
27. O'Roirdan TG, Amram JC. Effect of nebuliser configuration on delivery of aerosolized tobramycin. Am J Respir Crit Care Med 1995;151:A739.
28. Thomas SHL, O'Doherty MJ, Page CJ, Nunan TO, Bateman NT. Which apparatus for inhaled pentamidine? A comparison of pulmonary deposition via eight nebulisers. Eur Respir J 1991;4:616-22.
29. Smith G. A patient's view of cystic fibrosis. J Adolescent Health Care 1986;7:134-8.
30. Simon PP, Gemmell HG, Innes N, Davidson J, Smith FW, Legge JS, et al. Use of nebulised saline and nebulised terbutaline as an adjunct to chest physiotherapy. Thorax 1988;43:57-60.
31. Pavia D, Sutton PP, Lopez-Vidriero MT, Newman SP, Clarke SW. Drug effects on mucociliary clearance. Eur J Respir Dis 1983;64: (Suppl 128): 304-17.
32. Hung JCC, Hambleton G, Super M. Jet nebulisers for recombinant human DNase 1. Arch Dis Child 1994;71: 558-9.
33. O'Roirdan TG, Wilson JM, Robinson CB. Evaluation of delivery systems for aerosolization of recombinant gene therapy for cystic fibrosis. Am J Respir Crit Care Med 1995; 151:A19.
34. Shah PL, Scott SF, Fuchs HJ, Geddes DM, Hodson ME. Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I. Thorax 1995;50:333-8.
35. Cipolla D, Gonda I, Shire SJ. Characterisation of aerosols of human recombinant deoxyribrose nuclease 1 generated by jet nebulisers. Pharm Res 1994;2:491-8.
36. Malone RA, Hollie MC, Glynn-Barnhart A, Nelson HS. Optimal duration of nebulised albuterol therapy. Chest 1 1993;104:1114-8.
37. Steventon RD, Wilson RSE. Facemask or mouthpiece for delivery of nebulized bronchodilator aerosols. Br J Dis Chest 1981;75:88-90.
38. Wood DO, Chandler D, Dovedale AE. Two methods of administering nebulised salbutamol, a controlled study. Aust Paediatr J 1978;14:150-3.
39. Ruffin RE, Wolff RK, Dolovich MB, Rossman CM, Fitzgerald JO, Newhouse MT. Aerosol therapy with Sch 1000; short-term mucociliary clearance in normal and bronchitic subjects and toxicology in normal subjects. Chest 1978;73: 501-6.
40. Scheufler G. Ophthalmotonometry, pupil diameter and visual accommodation following repeated administration of Sch 1000 MDI in patients with glaucoma (abstract). Postgrad Med J 1975;51(Suppl 7): 132.
41. Thumm HW. Ophthalmic effects of high doses of Sch 1000 MDI in healthy volunteers and patients with glaucoma (abstract). Postgrad Med J 1975;51(Suppl 7): 132-3.
42. Samaniego F, Newman LS. Migratory aniscoria: a novel clinical entity (letter). Am Rev Respir Dis 1986;143:844.
43. Kalra L, Bone M. The effect of nebulized bronchodilator therapy on intraocular pressure in patients with glaucoma. Chest 1988;93:739-41.
44. Shah P, Dhurjon L, Metcalfe T, Gibson JM. Acute angle glaucoma associated with nebulized ipratropium bromide and salbutamol. BMJ 1992;304:40-1.
45. Medical Device Bulletin No. 9501. The reuse of medical devices supplied for single use only. London: Medical Devices Agency, 1995.
46. Higgs CMB, Harvey JE, Jones P, Tanser AR. Effect of long term domiciliary nebuliser therapy. Thorax 1984;39:689.
47. Hutchinson GR, Parker S, Pryor J. Home-use nebulisers: a potential source of Burkholderia cepacia and other colistin-resistant, gram negative bacteria in patients with cystic fibrosis. J Clin Microbiol 1996;34:584-7.
48. Dodd M, Eveleigh M. Nebulizer therapy your questions answered. How do I clean my nebulizer? National Asthma Training Centre and Medic-Aid Ltd, 1995: 11-12.